A stem cell trial on a dozen Type 1 diabetes patients suffering from a severe form of the disease has provided at least a temporary cure for 10 participants. The remaining two also dramatically reduced the amount of insulin they require daily. The treatment, with an infusion called Zimislecel, was created by Vertex Pharmaceuticals and has been the life's work of Boston-based researcher Dr. Douglas Melton, whose stem cell research began at Harvard University. He now works in the stem cell and gene therapy program at Vertex. Melton's interest in 'curing' diabetes began more than 25 years ago when his infant son and then adolescent daughter were both diagnosed with Type 1 diabetes.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
